Drugs / BCG
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07122414 | Aug 2024 → Oct 2027 expected | urinary bladder carcinoma | Suzhou Forlong Biotechnology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07122414 ↗ |
| Route | Other | “intravesical BCG” NCT07122414 ↗ |